India's rotavirus vaccine row: show me the data
This article was originally published in Scrip
A public interest litigation (PIL) has brought to the fore a simmering controversy over alleged safety signals concerning an indigenous oral rotavirus vaccine (Rotavac) developed through a unique public-private partnership in India.
You may also be interested in...
A public interest litigation (PIL) has sought to revive efforts to access segregated trial data from an indigenous oral rotavirus vaccine (Rotavac) in India amid concerns that it might be associated with a higher risk of intussusception in certain pockets of the country. And in a further dimension, an expert panel recently brought up a "representation" on the inclusion of intussusception in the vaccine's package insert.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Gland Pharma, controlled by Chinese group Fosun, makes shining debut on Indian stock markets despite a lukewarm response to its IPO. Will the buoyant market sentiment sustain amid edgy India-China relations?